REGULATED PRESS RELEASE published on 03/26/2026 at 07:30, 5 months 9 days ago BIOPHYTIS-LYNXKITE ALLIANCE INVITED TO NVIDIA CONFERENCE: UNLEASHING AI TO REVOLUTIONIZE LONGEVITY Biophytis SA participated in NVIDIA GTC conference to advance AI-driven drug discovery in longevity in collaboration with LynxKite Technologies and Nebius, positioning them at the forefront of innovation in the $1.5 trillion longevity market Longevity Biophytis SA AI-driven Drug Discovery NVIDIA GTC Conference LynxKite Technologies
PRESS RELEASE published on 03/26/2026 at 07:30, 5 months 9 days ago Annual results 2025 Netgem (Euronext Growth: ALNTG) reports 2025 annual results with €31.7M revenue, €1.9M operating income, and €0.05 dividend. Focus on recurring revenues and product strategy for hesitant telecom market Revenue Dividend Telecom Netgem ALNTG
PRESS RELEASE published on 03/26/2026 at 07:29, 5 months 9 days ago Hapag-Lloyd publishes 2025 annual report and proposes dividend of EUR 3.00 per share Hapag-Lloyd publishes 2025 annual report, proposes EUR 3.00 dividend per share. Earnings slightly below prior year, 2026 outlook uncertain due to geopolitical factors Dividend Proposal Hapag-Lloyd Earnings Geopolitical Uncertainty 2025 Annual Report
PRESS RELEASE published on 03/26/2026 at 07:29, 5 months 9 days ago Mister Spex Closes First Transformation Phase with Significant Earnings Improvement Mister Spex SE reports significant earnings improvement in 2025, achieving structural margin expansion and store profitability. Focus shifts to enhancing infrastructure and operational efficiency in 2026 Operational Efficiency Mister Spex SE Earnings Improvement Revenue Quality Infrastructure Modernisation
PRESS RELEASE published on 03/26/2026 at 07:29, 5 months 9 days ago BIOPHYTIS-LYNXKITE ALLIANCE INVITED TO NVIDIA CONFERENCE: UNLEASHING AI TO REVOLUTIONIZE LONGEVITY Biophytis announces participation at NVIDIA GTC conference, showcasing AI-driven drug discovery collaborations with LynxKite and Nebius to revolutionize longevity innovation Biophytis AI-driven Drug Discovery LynxKite NVIDIA GTC Longevity Innovation
PRESS RELEASE published on 03/26/2026 at 07:29, 5 months 9 days ago Financial year 2025: ElringKlinger enhances profitability while advancing its transformation ElringKlinger AG reports enhanced profitability and progress in transformation during the financial year 2025, with organic revenue growth and increased adjusted EBIT margin. Guidance for 2026 includes slight revenue growth and improved EBIT margin Profitability Transformation Organic Revenue Growth ElringKlinger AG Financial Year 2025
PRESS RELEASE published on 03/26/2026 at 07:29, 5 months 9 days ago DEUTZ generates growth and achieves one of the highest profits in its recent history despite challenging market conditions in 2025 DEUTZ achieves significant growth and high profits in 2025 despite challenging market conditions. Strategic transformation boosts revenue and profitability. New organizational structure aims for 2030 targets Transformation Growth 2025 Profits DEUTZ
PRESS RELEASE published on 03/26/2026 at 07:27, 5 months 9 days ago Delivery Hero reports adj EBITDA up 30% in 2025, as Quick Commerce and key markets gain momentum Delivery Hero SE reports 30% increase in adj EBITDA for 2025, showcasing growth and profitability. Strategic review and agreement for Taiwan sale Delivery Hero Strategic Review 2025 Results Adj EBITDA Taiwan Sale
PRESS RELEASE published on 03/26/2026 at 07:11, 5 months 9 days ago Berentzen-Gruppe Aktiengesellschaft publishes its 2025 Annual Report – Berentzen Group achieves significant consolidated profit Berentzen-Gruppe Aktiengesellschaft publishes its 2025 Annual Report with a significant consolidated profit of EUR 2.4 million. Forecast for the 2026 financial year presented Dividend Financial Forecast Consolidated Profit Berentzen-Gruppe Aktiengesellschaft 2025 Annual Report
PRESS RELEASE published on 03/26/2026 at 07:07, 5 months 9 days ago Heidelberg Pharma Announces Financial Figures and Reports on Business Performance in 2025 and Outlook for 2026 Heidelberg Pharma AG reports financial figures, business performance in 2025, and outlook for 2026, including CEO appointment, cost-cutting program, and extended cash runway. Fast Track designation for HDP-101 by FDA Financial Figures Outlook Business Performance Heidelberg Pharma Fast Track Designation
Published on 09/04/2026 at 14:30, 5 hours 33 minutes ago Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF)
Published on 09/04/2026 at 14:00, 6 hours 3 minutes ago Horizon Aircraft Appoints Tom Hearne to Board of Directors and Names Him Audit Committee Chair
Published on 09/04/2026 at 13:30, 6 hours 33 minutes ago Suntex Enterprises Launches Ambitious $1 Billion+ North American Real Estate Development Initiative
Published on 09/04/2026 at 13:00, 7 hours 3 minutes ago Storm Further Upsizes Private Placement to $3.2M
Published on 09/04/2026 at 08:02, 12 hours 1 minute ago Southern Energy Corp. Announces Restricted Share Award Grant
Published on 09/04/2026 at 19:20, 43 minutes ago Dahua Technology Showcases Integrated Smart Living and Innovations at IFA Berlin 2026
Published on 09/04/2026 at 18:50, 1 hour 13 minutes ago A&S Resources secures railway funding of USD$6 Billion to unlock $2.5 trillion iron ore asset
Published on 09/04/2026 at 18:05, 1 hour 58 minutes ago Grundig Unveils New Product Lineup at IFA 2026, Marking a New Phase in Strategic Partnership
Published on 09/04/2026 at 17:50, 2 hours 13 minutes ago CHiQ at IFA 2026: From Global Expansion to Deeper Local Engagement
Published on 09/04/2026 at 18:57, 1 hour 6 minutes ago Disclosure of transactions in own shares from September 1 to September 4, 2026
Published on 09/04/2026 at 17:45, 2 hours 18 minutes ago Declaration of voting rights at the end of August 2026
Published on 09/04/2026 at 17:45, 2 hours 18 minutes ago DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
Published on 09/04/2026 at 16:00, 4 hours 3 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of July 31, 2026
Published on 09/04/2026 at 16:00, 4 hours 3 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of August 31, 2026